Cost-Effective But Unaffordable: The CAR-T Conundrum

J Natl Cancer Inst. 2019 Jul 1;111(7):644-645. doi: 10.1093/jnci/djy195.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • B-Lymphocytes
  • Cell- and Tissue-Based Therapy
  • Child
  • Cost-Benefit Analysis
  • Humans
  • Immunotherapy, Adoptive
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma*
  • Receptors, Antigen, T-Cell
  • Receptors, Chimeric Antigen*

Substances

  • Receptors, Antigen, T-Cell
  • Receptors, Chimeric Antigen